Tysabri and Gastrointestinal inflammation - a phase IV clinical study of FDA data
Gastrointestinal inflammation is found among people who take Tysabri, especially for people who are female, 50-59 old, have been taking the drug for 2 - 5 years.
The phase IV clinical study analyzes which people take Tysabri and have Gastrointestinal inflammation. It is created by eHealthMe based on reports of 210,327 people who have side effects when taking Tysabri from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
210,327 people reported to have side effects when taking Tysabri.
Among them, 22 people (0.01%) have Gastrointestinal inflammation.
What is Tysabri?
Tysabri has active ingredients of natalizumab. It is often used in multiple sclerosis. eHealthMe is studying from 204,993 Tysabri users for its effectiveness, alternative drugs and more.
What is Gastrointestinal inflammation?
Gastrointestinal inflammation (inflammation of stomach and intestine) is found to be associated with 772 drugs and 511 conditions by eHealthMe.
Number of Tysabri and Gastrointestinal inflammation reports submitted per year:
Time on Tysabri when people have Gastrointestinal inflammation *:
- < 1 month: 0.0 %
- 1 - 6 months: 0.0 %
- 6 - 12 months: 0.0 %
- 1 - 2 years: 42.86 %
- 2 - 5 years: 42.86 %
- 5 - 10 years: 14.29 %
- 10+ years: 0.0 %
Gender of people who have Gastrointestinal inflammation when taking Tysabri *:
- female: 81.82 %
- male: 18.18 %
Age of people who have Gastrointestinal inflammation when taking Tysabri *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 6.67 %
- 20-29: 20.0 %
- 30-39: 20.0 %
- 40-49: 13.33 %
- 50-59: 26.67 %
- 60+: 13.33 %
Common drugs people take besides Tysabri *:
- Humira: 5 people, 22.73%
- Avonex: 4 people, 18.18%
- Remicade: 4 people, 18.18%
- Entyvio: 4 people, 18.18%
- Zopiclone: 1 person, 4.55%
- Junel 1.5/30: 1 person, 4.55%
- Aubagio: 1 person, 4.55%
- Copaxone: 1 person, 4.55%
- Dalfampridine: 1 person, 4.55%
- Desmopressin Acetate: 1 person, 4.55%
Common side effects people have besides Gastrointestinal inflammation *:
- Urinary Tract Infection: 5 people, 22.73%
- Drug Ineffective: 4 people, 18.18%
- Fatigue (feeling of tiredness): 4 people, 18.18%
- Weight Decreased: 3 people, 13.64%
- Hypotension (abnormally low blood pressure): 3 people, 13.64%
- Mycobacterium Avium Complex Infection: 3 people, 13.64%
- Dehydration (dryness resulting from the removal of water): 3 people, 13.64%
- Cytomegalovirus Colitis (an inflammation of the colon from virus): 3 people, 13.64%
- Colitis (inflammation of colon): 3 people, 13.64%
- Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect): 3 people, 13.64%
Common conditions people have *:
- Crohn's Disease (condition that causes inflammation of the gastrointestinal tract): 3 people, 13.64%
- Urination - Excessive At Night: 1 person, 4.55%
- Stress And Anxiety: 1 person, 4.55%
- Rectal Haemorrhage (bleeding from anus): 1 person, 4.55%
- Neuralgia (pain in one or more nerves): 1 person, 4.55%
- Muscle Spasticity (tight or stiff muscles and an inability to control those muscles): 1 person, 4.55%
- Metastases To Bone (cancer spreads to bone): 1 person, 4.55%
- Insomnia (sleeplessness): 1 person, 4.55%
- Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 4.55%
- Gait Disturbance: 1 person, 4.55%
* Approximation only. Some reports may have incomplete information.
Do you take Tysabri and have Gastrointestinal inflammation?Check whether Gastrointestinal inflammation is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related publications that referenced our studies
- Schwerd T, Pandey S, Yang HT, Bagola K, Jameson E, Jung J, Lachmann RH, Shah N, Patel SY, Booth C, Runz H, "Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann–Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn9s disease", Gut, 2016 Mar .
How severe was Gastrointestinal inflammation and when was it recovered:
Expand to all the drugs that have ingredients of natalizumab:
Alternative drugs to, pros and cons of Tysabri:
- Tysabri (204,993 reports)
Common Tysabri side effects:
Browse all side effects of Tysabri:a b c d e f g h i j k l m n o p q r s t u v w x y z
Gastrointestinal inflammation treatments and more:
- Gastrointestinal inflammation (7,706 reports)
COVID vaccines that are related to Gastrointestinal inflammation:
- Gastrointestinal inflammation in Moderna COVID Vaccine
- Gastrointestinal inflammation in Pfizer BioNTech Covid Vaccine
- Gastrointestinal inflammation in Johnson and Johnson Covid Vaccine
Common drugs associated with Gastrointestinal inflammation:
All the drugs that are associated with Gastrointestinal inflammation:
- Gastrointestinal inflammation (772 drugs)
Common conditions associated with Gastrointestinal inflammation:
All the conditions that are associated with Gastrointestinal inflammation:
- Gastrointestinal inflammation (511 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on natalizumab (the active ingredients of Tysabri) and Tysabri (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Nifedipine and Diabetes Mellitus Non Insulin-Dependent - now
- Esomeprazole Sodium and Gastritis - 2 seconds ago
- Paxil Cr and Oedema Peripheral - 3 seconds ago
- Augmentin and Metastases To Lung - 10 seconds ago
- Strontium Ranelate and Disability - 11 seconds ago
- Uniretic and Osteopenia - 25 seconds ago
- Combivir and Weakness - 26 seconds ago
- Magnesium and Radial Nerve Dysfunction - 46 seconds ago
- High Blood Pressure and Vulval Cellulitis - 52 seconds ago
- Lamictal and Euthyroid Sick Syndrome - a minute ago